Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Highlights and goals of IMPAKT 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3556

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Prof Martine Piccart talks to ecancer about heterogeneity of breast cancer tumours, advancements in technology and the future of treating breast cancer at IMPAKT 2012 in Brussels, May 2012.


IMPAKT 2012 focused on the latest developments in translational research, teaching young oncologists on how to treat patients in the coming years and especially on the heterogeneity of tumours.


New technologies hold the potential for understanding the evolution of breast cancer and the differences between primary tumours and metastases.


With HER tumours, each type of tumour, slow growing and highly proliferating, hold very specific molecular characteristics that can potentially unlock new understandings of the disease through the patient's immune system and the microenvironment.


Filming Supported by Amgen

Related videos

follow us

Breast Cancer CDK 4/6

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation